NPPA seeks clarification on Gilead's drug pricing plea

National Pharmaceutical Pricing Authority has sought clarifications from the company. Gilead had sought exemption from price control for its Tenofovir Alafenamide tablets (brand name Vemlidy) to capture a major chunk of Rs 140-crore market for chronic Hepatitis B in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2Ob3YG8
via IFTTT